Effect of a traditional medicine "Qurs-e Tabasheer" on diabetes and diabetic nephropathy

Effect of Qurs-e Tabasheer, a traditional Persian formula, on blood glucose and renal complications in patients with diabetic nephropathy, a randomized controlled trial

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220224054116N1

Enrollment

Registered

2022-05-16

Start date

2022-05-07

Completion date

Unknown

Last updated

2022-05-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetic nephropathy. Type 2 diabetes mellitus with kidney complications

Interventions

Intervention 1: Intervention group: This group receives Qurs-e Tabasheer (two tablets three times daily) for 12 weeks in addition to their standard treatment. Ingredients of Qurs-e Tabasheer are: Bamb

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with diabetes and diabetic nephropathy Patients receiving a stable dose of ACEI or ARB eGFR between 15 and 30 (stage 4 CKD) Albuminuria more than 30 mg/day Patients over 18 years old

Exclusion criteria

Exclusion criteria: Patients with liver disease, active infection, malignancy Patients with kidney disease from nondiabetic cause Problems with nutrient absorption in gastrointestinal tract Sensitivity to drug components Pregnant or lactating women

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;Serum creatinine. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;LDL cholesterol (Low Density Lipoprotein). Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;Urinary albumin. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Urine test.;Blood urea nitrogen. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;Estimated glomerular filtration rate(eGFR). Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Calculating by the formula Cockcroft - Gault.	—

Measure

Time frame

Fasting blood sugar. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;Serum creatinine. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;LDL cholesterol (Low Density Lipoprotein). Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;Urinary albumin. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Urine test.;Blood urea nitrogen. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Blood test.;Estimated glomerular filtration rate(eGFR). Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Calculating by the formula Cockcroft - Gault.

—

Secondary

Measure	Time frame
Quality of Life score. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Diabetes Quality of Life (DQOL) Questionnaire.;Sexual function score. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: FSFI Questionnaire for women and IIEF Questionnaire for men.	—

Measure

Time frame

Quality of Life score. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: Diabetes Quality of Life (DQOL) Questionnaire.;Sexual function score. Timepoint: At the beginning of the study and at the end of the 12th week after starting the medication. Method of measurement: FSFI Questionnaire for women and IIEF Questionnaire for men.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Mahdi Ahmadian-Attari

Alborz University of Medical Sciences

ahmadian.attari@gmail.com+98 26 3256 7175

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026